Genetic Alteration, Prognostic and Immunological Role of Acyl-CoA Synthetase Long-Chain Family Member 4 in a Pan-Cancer Analysis

Yongsheng Yu†, Xuepu Sun‡, Fei Chen³ and Miao Liu⁴*

†Department of General Surgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China, ‡Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China, ³Department of General Surgery, Linyi Traditional Chinese Medicine Hospital, Linyi, China, ⁴Department of Pathology, Beidahuang Industry Group General Hospital, Harbin, China

Acyl-CoA Synthetase long-chain family member 4 (ACSL4) is a member of acyl-CoA synthetase protein long-chain family, which is associated with amino acid synthesis, lipid synthesis and lipid peroxidation dependent iron death. However, the role of ACSL4 in generalized carcinoma remains unclear. We aim to analyze the expression and prognostic value of ACSL4 in pan-cancer, and further explore the correlation between ACSL4 and immune infiltration. Through ONCOMINE, TIMER (Tumor Immune Estimation Resource), GEPIA (Gene expression Profiling Interactive), UALCAN and HPA, ACSL4 expression patterns of in pan-cancer were analyzed. The prognostic value of ACSL4 was analyzed using PrognoScan and Kaplan-Meier Plotter databases. Furthermore, gene variation and epigenetic modification of ACSL4 were analyzed by cBioPortal and GSCA databases. Meanwhile, GEPIA and TIMER databases applied to evaluate the relationship between ACSL4 expression and immune infiltration. These results indicate that ACSL4 expression is down-regulated and associated with prognosis in most tumors. In general, lower ACSL4 expression shows more beneficial prognosis. The most common genetic alteration of ACSL4 is point mutation. ACSL4 is negatively correlated with DNA methylation levels in most cancers. ACSL4 mutations or hypomethylation are associated with poor prognosis. In addition, ACSL4 is positively correlated with immune infiltration in cancers. ACSL4 and immune infiltration are strongly associated with prognosis in BRCA (Breast invasive carcinoma) and SKCM (Skin Cutaneous Melanoma). ACSL4 mutation caused significant changes of immune infiltration in UCEC (Uterine Corpus Endometrial Carcinoma) and SARC (Sarcoma). ACSL4 may be a promising prognostic biomarker for pan-cancer and is closely associated with immune infiltration in the tumor microenvironment.

Keywords: ACSL4, Pan-cancer analysis, prognosis, immunological, genetic alteration
INTRODUCTION

Cancer relies on metabolic reprogramming to drive malignant transformation (Boroughs and DeBerardinis, 2015). More and more tumor metabolic phenotypes have been identified and validated and are becoming biomarkers for the disease (Chen et al., 2019; Qin et al., 2020). Alterations in glucose and lipid metabolic pathways are one of the most striking metabolic features present in many different types of cancer. Changes in lipid metabolism of cancer cells showed increased proliferation, progression and metastasis (Cheng et al., 2018; Snaebjornsson et al., 2020). Activation of fatty acids catalyzed by acyl-coA synthase (ACS) is essential for the metabolism of both extracellular derived and de novo synthesized fatty acids. There are five members of the ACSL family, namely ACSL1, ACSL3, ACSL4, ACSL5 and ACSL6. Previous studies have shown that almost all ACSL members are deregulated in clinical cancers, which is conducive to excessive lipid biosynthesis and deposition, and ultimately makes the body susceptible to metabolic disorders and carcinogenesis (Tang et al., 2018). ACSL1 and ACSL4 are overexpressed in most cancer types and may have synergistic effects to promote unregulated cell growth, promote tumor invasion and evade programmed cell death (Sánchez-Martínez et al., 2017; Yen et al., 2017). While ACSL5 showed the opposite effect and was associated with a good prognosis in breast cancer patients. In addition, each with unique substrate of the ACSL family preferences and enzyme activity at different cellular sites, which depended on the chain length and saturation status of fatty acids (Grevengoed et al., 2014). ACSL4 is mainly present in peroxisome, mitochondria and endoplasmic reticulum. In contrast, ACSL4 prefers longer polyunsaturated fatty acids (PUFA) as substrates, such as arachidonic acid. It catalyzes the conversion of free arachidonic acid to arachidonic acid-coA ester, which is then esterified by interaction with membrane phospholipids and leads to ferroptosis (Küh et al., 2014; Kagan et al., 2017; Sánchez-Martínez et al., 2017). Recent studies have linked ferroptosis to a variety of cancers. Ferroptosis is a new iron-dependent form of regulated cell death, which characterized by iron-dependent accumulation of lipid-ROS and subsequent depletion of polyunsaturated fatty acid phospholipids (PUFA-PLS) (Hirschhorn and Stockwell, 2019). ACSL4 has been shown to be overexpressed in several cancer types, including colon cancer, breast cancer, liver and prostate cancer (Sánchez-Martínez et al., 2017; Wang J. et al., 2020; Chen et al., 2020; Ma et al., 2021; Sha et al., 2021), but often down-regulated in gastric cancer and lung cancer (Ye et al., 2016; Zhang et al., 2021).

As a percentage of genome length, the level of Copy number variation (CNV) in the tumor genome reflects the degree of tumor genome change (Hieronymus et al., 2018). The level of genomic copy number alteration is associated with prognosis in many cancers (Cao et al., 2019; Su et al., 2019; Lu et al., 2020; Woo et al., 2021). Recent analyses have linked cancer genomic characteristics, including TMB and CNA, to anti-tumor immunity. Studies suggest that high mutation load and low aneuploidy may be associated with increased T cell response (Budczies et al., 2018). The tumor microenvironment (TME) is composed of cellular components and non-cellular extracellular matrix. Cellular components include stromal fibroblasts, infiltrating immune cells, blood and lymphatic networks. TME is usually characterized by nutritional competition, low PH, hypoxia, and metabolite accumulation. This environment results in immunosuppression or a tolerant phenotype of immune cells and promotes metabolism that relies more on oxidative phosphorylation and fatty acid oxidation to meet energy requirements (Bader et al., 2020). The role of metabolic reprogramming in the activation and differentiation of immune cells has also attracted increasing attention (Biswas, 2015). As an important part of tumor environment, immune cell infiltration has been extensively studied for its role and prognostic value in various malignant tumors. With the development of immunotherapy, potential targets have been gradually discovered. But only a small percentage of patients with specific cancer types respond well to current immunotherapies. Therefore, it is necessary to explore the characteristics of various immune cells and their relationship with tumor interaction.

In this study, we analyzed the expression pattern and prognostic value of ACSL4 in various cancers using data from multiple public databases and discovered the impact of genetic changes of ACSL4 on prognosis. In addition, the potential relationship between ACSL4 expression and immune infiltration level was discussed. The results suggest that ACSL4 can affect the prognosis of cancer patients through its interaction with invasive immune cells.

MATERIALS AND METHODS

Differential Gene Expression Analysis of ACSL4

We used Oncomine (www.oncomine.org), The TIMER (Tumor Immune Estimation Resource, https://cistrome.shinyapps.io/timer/) and GEPIA (Gene Expression Profiling Interactive Analysis, http://gepia.cancer-pku.cn/) to analyze ACSL4 expression in pan-cancer (Rhodes et al., 2004; Li et al., 2017; Tang et al., 2017). Specifically, the Oncomine Gene Expression Array Dataset is an online oncogene microarray database and data mining platform containing 65 gene expression datasets, including nearly 48 million gene expression measurements from more than 4,700 microarray experiments. Thresholds was determined based on the following values: p = 0.001, folding change 1.5, and gene ranking of all. TIMER is a visual and interactive site for comprehensive research on tumor immune interactions. It precalculated the levels of six tumor osmotic immune subsets for 10,897 tumors from 32 cancer types to explore associations between immune osmosis and various factors, including gene expression, clinical outcomes, somatic mutations, and somatic copy number changes. GEPIA is an interactive web-based application for gene expression analysis of 9736 tumors and 8587 normal samples based on TCGA and GTEx databases. It can carry out differential expression analysis, Survival analysis, Correlation analysis and similar gene detection analysis. The method for differential analysis is one-way ANOVA, |log2FC| = 1 and p = 0.01 is used as the cut-off
standard. The Cancer Cell Line Encyclopedia (CCLE) (https://sites.broadinstitute.org/ccle/) is an effort to generate large-scale profiling data sets across nearly 1,000 cell lines from diverse tissue lineages. (Nusinow et al., 2020). DepMap Portal can be used for CCLE Data Visualization and Analysis. ACSL4 expression in cancer cell lines was validated by DepMap Portal.

The types of cancer acronyms analyzed in this study are as follows: ACC (adenocortical carcinoma); BLCA (bladder urothelial carcinoma); BRCA (breast invasive carcinoma); CESC (cervical squamous cell carcinoma); CHOL (cholangiocarcinoma); COAD (colon adenocarcinoma); DLBC (lymphoid neoplasm diffuse large B cell lymphoma); ESCA (esophageal carcinoma); GBM (glioblastoma multiforme); HNSC (head and neck squamous cell carcinoma); KICH (kidney chromophobe); KIRC (kidney renal clear cell carcinoma); KIRP (kidney renal papillary cell carcinoma); LAML (lacute myeloid leukemia); LGG (brain lower grade glioma); LIHC (liver hepatocellular carcinoma); LUAD (lung adenocarcinoma); LUSC (lung squamous cell carcinoma); MESO (mesothelioma); OV (ovarian serous cystadenocarcinoma); PAAD (pancreatic adenocarcinoma); PCPG (pheochromocytoma and paraganglioma); PRAD (prostate adenocarcinoma); Read (rectum adenocarcinoma); SARC (sarcoma); SKCM (skin cutaneous melanoma); STAD (stomach adenocarcinoma); TGCT (testicular germ cell tumors); THCA (thyroid carcinoma); THYM (thymoma); UCEC (uterine corpus endometrial carcinoma); UCEC (uterine carinosarcoma); and UVM (uveal melanoma).

**Differentially Expressed at ACSL4 Protein Level**

UALCAN (http://ualcan.path.uab.edu/analysis-prot.html) is used to analyze the cancer Omics data interactive Web resources (Chandrashekar et al., 2017). It analyzed protein expression using TCGA level 3 RNA-SEQ and clinical data from 31 cancer types. In this study, protein expression of ACSL4 between different cancer tissues and normal tissues was analyzed according to CPTAC workflow. \( p < 0.05 \) was considered to be significant. The HPA (Human Protein Atlas, www.proteinatlas.org) is a valuable tool for studying protein localization and expression in human tissues and cells, combining antibody-based approaches with transcriptional data. It has more than 10 million images showing patterns of protein expression at the single-cell level (Thul and Lindskog, 2018). In this study, immunohistochemical images of ACSL4 protein expression between normal and cancer tissues were observed by HPA.

**Analysis of ACSL4 Gene Variation**

We used the cBio Cancer Genomics Portal (http://cbioportal.org) and GSCA (http://bioinfo.life.hust.edu.cn/GSCA/#/) to analyze variations in ACSL4 in different cancers, including mutations and copy number abnormalities (Cerami et al., 2012; Liu et al., 2018). UALCAN and MethSurv were used to analyze ACSL4 methylation and its correlation with survival prognosis in different cancers (Modhukur et al., 2018). Specifically, cBioPortal is an open platform for cancer genomics, providing data from more than 5,000 tumor samples from 20 cancer studies. The portal also includes copy number changes, changes in mRNA expression based on microarray and RNA sequencing, DNA methylation values, and protein and phosphoprotein levels. GSCA is provide a series of services to perform gene set genomic (Expression, SNV, CNV and methylation) and immunogenomic (24 immune cells) analyses. MethSurv is a survival analysis network tool based on CpG methylation pattern. It includes 7358 methyroles from 25 different human Bombs. Survival analysis of patient methylation levels at any CpG site (probe) was performed using the Cox proportional hazard model. Hazard ratio (HR) with 95% CI is derived from Cox fitting.

**Survival Prognosis Analysis of ACSL4**

We use PrognoScan (http://www.abren.net/PrognoScan/), Kaplan-Meier (https://kmplot.com/analysis/) to analyzed the correlation between ACSL4 expression and survival was found in different carcinoma (Mizuno et al., 2009; Yuan et al., 2019). PrognoScan is a clinically annotated and extensive publicly available cancer microarray dataset for assessing the biological relationship between gene expression and prognosis. A univariate Cox \( p < 0.05 \) was defined as statistically significant. Kaplan-Meier is a powerful online tool that can be used to assess the effect of 54,000 genes on survival in 21 cancer types. We analyzed the relationship of ACSL4 expression with overall survival (OS) and relapse-free survival (RFS) in different cancer, Hazard ratios (HR) with 95% confidence intervals (CI) and log-rank P-values were calculated.

**Analysis of ACSL4 Expression and Immune Cell Infiltration Level**

We used TIMER database to analyze the correlation between ACSL4 expression and the level of immune cell infiltration, including CD4+ T cells, CD8+ T cells, macrophages, neutrophils, monocytes, NK, DC, cancer-associated fibroblast (CAF) and Myeloid derived suppressor cell (MDSC). We used GSCA to analyze the correlation between single nucleotide variation (SNV), CNV levels in ACSL4 and immune cell infiltration levels in different cancers. Meanwhile, TIMER and GEPIA were used to analyze the correlation between ACSL4 and immune cell markers. Correlation analysis was determined by Spearman. \( p < 0.05 \) was considered statistically significant.

**ACSL4 Related Drugs Discovery in CMap**

The Connectivity Map (https://clue.io/cmap), or CMap, is an open database that can be used to identify connections among small molecules which sharing a mechanism of chemicals, physiological processes and action, and then predict potential drugs in silicon (Wang C. Y. et al., 2020). The Touchstone module can be used to explore connectivities between signatures from ~3,000 drugs and genetic loss/gain of function of ~2,000 genes. Sets of compound perturbagens with enrichment scores above 90 (similar) and below -90 (opposing). We used CMap analysis tools to identify the association between ACSL4 and drugs.
RESULTS

Differential Expression Analysis ACSL4 Between Tumor and Normal Samples

To evaluate ACSL4 mRNA expression patterns in different cancers, we analyzed ACSL4 expression between normal tissues and tumors using Oncomine database (Figure 1A). The results showed that compared with normal tissues, ACSL4 expression was higher in colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lymphoma, myeloma, and pancreatic cancer, but decreased in bladder cancer, brain and CNS cancer, breast cancer, leukemia, lung cancer, and pancreatic cancer. Notably, in the pancreatic cancer data set, one went up and the other went down. Further using the TIMER database to verify the differences between ACSL4 in different tumors and normal tissues (Figure 1B). The results showed that ACSL4 was
FIGURE 3 | Survival data evaluating the prognostic value of ACSL4. (A). Correlation between ACSL4 and prognosis of various types of cancer in the PrognoScan. DMFS (n = 286) in breast cancer cohort GSE 2034. DSS (n = 159) in breast cancer cohort GSE1456-GPL96. OS (n = 159) in breast cancer cohort GSE1456-GPL96. DSS (n = 177) in colorectal cancer cohort GSE17536. OS (n = 177) in colorectal cancer cohort GSE17536. RFS (n = 204) in lung cancer (Adenocarcinoma) cohort GSE31210. OS (n = 70) in brain cancer (Glioblastoma) cohort GSE7696. DMFS, distant metastasis-free survival; OS, overall survival; DSS, disease-specific survival; (Continued)
significantly increased in CHOL, COAD, ESCA, LIHC, STAD and HNSC (p < 0.05). In addition, ACSL4 was significantly decreased in BRCA Breast invasive carcinoma, KICH, KIRP, GBM, PAAD, SKCM, KIRC, PRAD and UCEC (p < 0.05). We also performed analysis using GEPIA and obtained consistent results (Supplementary Figure S1). By assembling the Cancer Cell Line Encyclopedia (CCLE), we further analyzed the expression of ACSL4 in cancer cell lines. The results showed that ACSL4 was highly dependent on leukemia, bladder cancer, lymphoma and lung cancer cell lines. The expression of ACSL4 was low in breast Cancer and prostate cancer cell lines, but high in liver cancer, thyroid cancer and skin cancer cell lines, which was consistent with the previous results (Supplementary Table S1).

In order to determine the protein expression of ACSL4 in various cancers, the UALCAN database was used to analyze the ACSL4 protein expression. The results showed that compared with normal tissues, ACSL4 expression was higher in COAD, OV and UCEC tissues (p < 0.05), but lower in BRAC and KIRC tissues (p < 0.05, Figure 2A). This was consistent with ACSL4 mRNA expression in TIMER and GEPIA databases. Meanwhile, compared with normal tissues, ACSL4 was strongly positive in endometrial cancer and liver cancer, and low in breast, lung, and renal cell carcinoma tissues in the human protein atlas (Figure 2B).

**Prognostic Analysis of ACSL4 in Patients with Different Cancers**

The relationship between ACSL4 expression and prognosis in patients with various cancers was analyzed using the PrognoScan database (Figure 3A). We found that ACSL4 was associated with prognosis of four cancer types. The patients with high expression of ACSL4 have poor prognosis in colorectal cancer (OS: total number, 177; 95% CI, 1.36–3.28, HR, 2.11; Cox P, 0.000896,433; DSS: total number, 177; 95% CI, 1.19–3.25, HR, 1.96; Cox P, 0.00877,945). While low expression of ACSL4 has shown a beneficial role in pan-cancer.

**Genetic Alterations of ACSL4 in Different Cancers**

Using the cBioPortal database, we explored the genetic changes of ACSL4 in various cancers and their correlation with patients’ OS and PFS in TCGA-Pan cancer panel. In 10,953 patients with ACSL4 mutation information from the TCGA dataset, the percentage of ACSL4 mutation was 1.6% (Figure 4A). The most common mutations are point mutations, which are mainly found in endometrial cancer, melanoma, cervical squamore cell carcinoma, pleural mesothelioma and Glioblastoma. All cases of Melanoma have point mutations. “Amplification” exists in all cases of Renal clear cell carcinoma, Hepatocellular carcinoma and well-differentiated thyroid cancer. The types and mutation sites of ACSL4 gene are shown in the figure (Figure 4B). Among mutations, missense mutation has the highest frequency. Critical changes in ACSL4 function are mutations in AMP-biding containing the active site of ACSL4. The most common site was X60-splice/R60C, which was found in 3 cases of endometrial carcinoma and 1 case of cutaneous melanoma. We explored the potential relationship between genetic changes in ACSL4 and clinical outcomes in patients with different types of cancer. The results showed that the OS (p = 0.034), DFS (p = 0.0278) and PFS (p = 0.005) of...
patients with ACSL4 mutation were significantly higher than those without ACSL4 mutation (Figure 4C). In short, genetic alterations in ACSL4 can significantly affect patient outcomes. Analysis of CCLE database showed that “copy number amplification” occurred frequently in cervical cancer, fibroblast, ovarian cancer, breast cancer and endometrial/uterine cancer. The most frequently mutated entity is lymphoma, followed by Leukemia. In addition, endometrial/uterine cancer and lung cancer mutation frequency is high, which is consistent with cBioPortal results (Supplementary Table S1).

Meanwhile, GSCA database was used to analyze the SNV of ACSL4, and SNV was found in 19 kinds of cancer (Figure 5A). Consistent with cBioPortal, mutations were most common in UCEC and SKCM. Moreover, patients with ACSL4 mutations had a shorter overall survival time than those with wild-type in SKCM (HR, 2.76, Cox $p = 0.01$), while had a longer PFS than those with wild-type in UCEC (HR, 0.29, Cox $p = 0.01$) (Figure 5B). CNA is a common genetic alteration associated with the occurrence and progression of cancer by regulating the expression of tumor-related genes (Davoli et al., 2017). We analyzed the CNV of ACSL4 and the correlation between CNV and mRNA expression through GSCA database (Figure 5C). The results showed that ACSL4 CNV was positively correlated with mRNA expression in 10 cancers, including BLCA, BRCA, ESCA, HNSC, LUAD, LUSC, PAAD, PRAD, SARC and STAD. Only in KIRP, ACSL4 CNV was negatively correlated with mRNA expression. Similarly, we
assessed the effect of ACSL4 CNV on prognosis in patients with various cancers. In CSEC, KIRP, and LAML, patients with copy number deletion had a worse prognosis, while patients with copy number amplification had a worse prognosis in UCEC (Figure 5D).

DNA methylation regulates gene expression and closure and is closely related to human development and tumorigenesis. Subsequently, ACSL4 methylation in different cancers was analyzed using the UALCAN database (Figure 6A). The results showed that ACSL4 was hypomethylated in BLCA, BRCA, LIHC, STAD and TCGT. We found that lowly ACSL4 express tumors presented with decreased DNA methylation level of ACSL4, including BLCA and BRCA. In addition, DNA methylation of ACSL4 had higher levels in PRAD and UCEC. Similar results were obtained in GSCA database. ACSL4 was hypomethylated in LIHC and THCA, while it was hypermethylated in PRAD (Supplementary Figure S3A). Contrary to the UALCAN database results, ACSL4 was hypomethylated in UCEC. We further analyzed the correlation between ACSL4 methylation level and mRNA expression. The results showed that ACSL4 methylation was inversely correlated with mRNA in most cancers, including BRCA, CESC, COAD, ESCA, GBM, HNSC, KIRP, KIRC, LAML, LIHC, PCPG, PRAD, PEAD, SARC, SKCM, STAD, TGCT, THCA and UCEC. In BRCA, LIHC, LUSC, and ESCA (Supplementary Figure S3B). ACSL4 methylation levels were associated with poor prognosis (Figure 6B). The DNA methylation level of ACSL4 and the prognostic value of each single CpG were analyzed by MethSurv database (Supplementary Figure S3C). Compared with patients with ACSL4 hypermethylation, Hypomethylation was associated with poorer prognosis in 11 cancers, including BRCA, CESC, COAD, ESCA, GBM, KIRP, LGG, LIHC, STAD, SKCM and
UCEC. Which is located in the CPG island site prognosis is poorer, including cg0544164, cg06822229, cg10721440 (Supplementary Figure S4). Patients with ACSL4 hypermethylation had poorer prognosis and survival in other cancers: ACC, HNSC, KIRC, LUSC, PAAD and UCS.

Analysis of Immune Infiltration of ACSL4 in Different Cancers

Studies have shown that tumor-infiltrating lymphocytes are associated with cancer survival. The correlation between ACSL4 expression and TIL level was analyzed by TISIDB database. The heat map showed that ACSL4 was positively correlated with most immune cells (Supplementary Figure S5). We also evaluated the association between ACSL4 expression and tumor-infiltrating immune cells in the TIMER database (Figure 7A). The results showed that ACSL4 expression was significantly associated with NK, B cells, macrophages, DC, CD4+ T cells, CD8+ T cells, monocytes and neutrophil infiltration in 13, 16, 19, 24, 25, 26, 28 and 31 cancer types. ACSL4 was positively correlated with neutrophils, CD4+ T cells and monocyte infiltration. There was no correlation between ACSL4 expression and immune cell infiltration in UCS. In addition, we also found that the cancer with high ACSL4
expression was positively correlated with the infiltration level of MDSC, including COAD, LIHC and STAD, whereas the cancer with low ACSL4 expression was negatively correlated with the infiltration level of MDSC, including BRCA, KIRC, LUSC, GBM and SKCM.

We further analyzed the effects of ACSL4 and immune cell infiltration levels on survival outcomes. The results showed that MDSC infiltration level was correlated with the prognosis of 16 types of Cancer patients, while neutrophils, cancer-associated fibroblast (CAF) and DC were correlated with the prognosis of 10, nine and nine types of Cancer patients, respectively. And in BRCA and SKCM, ACSL4 and the level of immune cell infiltration are closely related to survival prognosis (Figure 7B). These results indicate that ACSL4 plays an important role in regulating the immune cells infiltration in BRCA and SKCM, especially monocytes, DC and MDSC.

In addition, we analyzed the effect of ACSL4 mutation on immune cell levels in various cancers by Mutation module. The results showed that ACSL4 mutation caused significant changes in the levels of various immune cells, especially in UCEC and SARC. Compared with ACSL4 wild type, ACSL4 mutation caused significant changes in CD4+ T cells, DC, macrophages and CAF, and showed opposite trends in both types of cancer (Supplementary Figure S6A). Similarly, the SCAN module was used to analyze the influence of ACSL4 on the level of immune cell invasion in High Amplification or Deep Deletion. The results showed that abnormality of ACSL4 at different copy numbers mainly caused changes in CAF levels, including HNSC, LGG, OV and BRCA (Supplementary Figure S6B). In addition, it can also cause changes in neutrophils, CD8+ T cells, DC, NK and Tfh infiltration levels.

Analysis of Immunoinfiltrating Cell Markers of ACSL4 in Various Cancers
Next, we analyzed the correlation between ACSL4 and immunoinfiltrating cell markers through TIMER and GEPIA databases respectively. We selected cancer types, mainly BRCA and SKCM, that express poor prognosis in cancers and are related to the level of immune cell infiltration and affect prognosis. UCS as a control. Immune cells include B cells, T cells (general), CD8+ T cells, Tfh, Treg, Exhaust T cells, TAM, M1 and M2 macrophages, monocytes, NK, neutrophils, DC, CAF and MDSC. After adjusting for tumor purity, ACSL4 expression was significantly associated with CCL2, CD68, IL10 of TAM, CD113, MS4A4A, VSIG4 of M2
| Cell type | Gene markers | BRCA | Purity | SKCM | Purity | UCS | Purity |
|-----------|--------------|------|--------|------|--------|-----|--------|
| **B**    | CD19        | 0.275 *** | 0.096  |      |        |     |        |
|          | CD79A       | 0.324 *** | 0.138  |      |        |     |        |
|          | CD3         | 0.404 *** | 0.241  |      |        |     |        |
|          | CD33        | 0.436 *** | 0.278  |      |        |     |        |
|          | CD68        | 0.458 *** | 0.577  |      |        |     |        |
|          | TCRG8       | 0.5     | 0.444  |      |        |     |        |
|          | Neutrophil  | 0.637   | 0.6    |      |        |     |        |
|          | Exhaust T   | 0.432   | 0.313  |      |        |     |        |
|          | MDSC        | 0.284   | 0.28   |      |        |     |        |
|          | M2          | 0.557   | 0.5    |      |        |     |        |
|          | monocyte    | 0.585   | 0.525  |      |        |     |        |
|          | NK          | 0.445   | 0.359  |      |        |     |        |
|          | Neutrophil  | 0.365   | 0.199  |      |        |     |        |
| **T**    | CD2         | 0.457   | 0.314  |      |        |     |        |
|          | CD3D        | 0.436   | 0.278  |      |        |     |        |
|          | CD68        | 0.514   | 0.422  |      |        |     |        |
|          | TAM         | 0.5     | 0.444  |      |        |     |        |
|          | TCRG8       | 0.5     | 0.444  |      |        |     |        |
|          | Neutrophil  | 0.432   | 0.313  |      |        |     |        |
|          | MDSC        | 0.284   | 0.28   |      |        |     |        |
|          | M2          | 0.557   | 0.5    |      |        |     |        |
|          | monocyte    | 0.585   | 0.525  |      |        |     |        |
|          | NK          | 0.445   | 0.359  |      |        |     |        |
|          | Neutrophil  | 0.365   | 0.199  |      |        |     |        |

BRCA, breast invasive carcinoma; SKCM, skin cutaneous melanoma; UCS, uterine carcinosarcoma.

None, correlation without adjustment; Purity, correlation adjusted for tumor purity; Cor, R value of Spearman’s correlation; *p < 0.05; **p < 0.01; ***p < 0.001.
macrophages, and CD86 and CSF1R of monocytes in BRCA and SKCM.

In BRCA and SKCM, DC markers (CD1C, GAX, HLA-DPA1, HLA-DPB1, HLA-DPB2, HLA-DRA and NRP1) were significantly correlated with ACSL4 expression levels (Table 1). This supports that ACSL4 expression is closely related to DC infiltration, thus affecting the prognosis and survival of patients. Similarly, CAF markers (HGF, PDGFRB, FGB1, THBS1) and MDSC markers (CD14, CD33) were positively correlated with ACSL4 expression in BRCA and SKCM. These results suggest that ACSL4 plays a role in the immunosuppressive state of cancer. In order to verify the results of TIMER analysis, GEPIA database was further used to analyze the correlation between ACSL4 and immune cell markers (Table 2). The results were consistent with the TIMER database. In BRCA and SKCM, ACSL4 expression was significantly correlated with CD8+ T cells, TAM, M2 macrophages, monocytes, CAF and MDSC markers. There was no correlation between ACSL4 and DC markers CD1C and HLA-DQB1 in SKCM. Other markers were correlated with both cancers.

### Identification of ACSL4 Related Compounds

The Connectivity Map was used as a first step in the drug discovery process. By comparing the queried and existing gene signatures, links can be found between gene knockout/overexpression or small molecules with similar or opposite effects (Lamb, 2007). Their related transcriptional effects suggest they confer related physiological effects on the cell. Genes with positive and negative scores have similar and opposite gene characteristics to ACSL4 expression, respectively. Connections were viewed as a heat map ranked by the summary connectivity score. Heat map showed that compounds with high similarity to ACSL4 included inhibitor of Insulin Growth factor 1 receptor protein Tyrosine kinase, nalbuphine opioid receptor agonist, opioid receptor antagonist, EGFR inhibitor, Cytochrome P450 inhibitor and carcinoma cell growth inhibitor. (Figure 8).

### DISCUSSION

Metabolic reprogramming is one of the hallmarks of cancer (Hanahan and Weinberg, 2011). Alterations in lipid metabolism, including catabolism and anabolism, are part of metabolic reprogramming that occurs in tumor cells to promote gene mutations, loss of tumor suppressors, and epigenetic modifications (Currie et al., 2013). Free fatty acids are converted into fatty acyl-coA synthase in an ATP-dependent manner, which causes membrane phospholipid biosynthesis, energy utilization and storage, lipid signaling and other physiological and metabolic processes (Coleman et al., 2000). Dysregulation of fatty acid metabolism leads to excessive lipid biosynthesis and deposition, which promotes the occurrence and development of cancer (Tang et al., 2018). ACSL4 is a key factor involved in metabolism-related diseases. Recent studies have shown that ACSL4 promotes arachidonic acid (AA) and

---

**TABLE 2 | Correlations between ACSL4 and Gene Markers of CD8+ T cell, TAM, M2, Neutrophil, CAF in GEPIA.**

| Cell type | Gene markers | BRCA  R  p   | SKCM  R  p   | UCS  R  p   |
|-----------|--------------|--------------|--------------|------------|
| CD8+T cell | CD8A         | 0.21 ***     | 0.16 ***     | 0.024 0.86  |
|           | CD8B         | 0.15 **      | 0.13 *       | -0.022 0.87|
| TAM       | COL2         | 0.48 ***     | 0.14 *       | 0.012 0.93 |
|           | IL10         | 0.45 ***     | 0.25 ***     | 0.068 0.61 |
|           | CD68         | 0.39 ***     | 0.31 ***     | 0.089 0.51 |
| M2        | CD163        | 0.34 ***     | 0.31 ***     | 0.089 0.51 |
|           | VSIG4        | 0.33 ***     | 0.25 ***     | 0.2 0.13 |
|           | MS4A4A       | 0.43 ***     | 0.32 ***     | 0.7 0.21 |
| Neutrophil | CD86         | 0.44 ***     | 0.33 ***     | 0.21 0.12 |
|           | CSF1R        | 0.43 ***     | 0.3 ***      | 0.2 0.14 |
| CAF       | HGF          | 0.25 ***     | 0.13 *       | 0.043 0.75 |
|           | PDGFRB       | 0.25 ***     | 0.16 **      | -0.05 0.71 |
|           | TGFB1        | 0.15 ***     | 0.27 ***     | 0.24 0.074|
|           | THBS1        | 0.28 ***     | 0.21 ***     | 0.18 0.19 |
| CAF       | CD14         | 0.18 ***     | 0.21 ***     | 0.17 0.2  |
|           | CD33         | 0.33 ***     | 0.22 ***     | 0.16 0.28 |
| DC        | CD1C         | 0.22 ***     | 0.025 0.59   | 0.062 0.66 |
|           | HLA-DPB1     | 0.23 ***     | 0.19 ***     | 0.1 0.45 |
|           | HLA-DQB1     | 0.13 ***     | 0.078 0.095  | 0.15 0.28 |
|           | HLA-DRA      | 0.33 ***     | 0.25 ***     | 0.16 0.22 |
|           | HLA-DPA1     | 0.33 ***     | 0.19 ***     | 0.098 0.47 |
|           | NRP1         | 0.51 ***     | 0.39 ***     | 0.3 0.022|
|           | ITGAX        | 0.31 ***     | 0.21 ***     | 0.23 0.082|

BRCA, breast invasive carcinoma; SKCM, skin cutaneous melanoma; UCS, uterine carcinosarcoma. Cor, R value of Spearman’s correlation. *p < 0.01; **p < 0.001; ***p < 0.0001.
epinephrine lipid peroxidation, participating in ferroptosis-related processes, and overexpression of ACSL4 promotes ferroptosis (Kagan et al., 2017; Cheng et al., 2020). Different from apoptosis, necrosis and autophagy, iron death is an iron-dependent, lipid peroxidation mediated form of cell death (Dixon et al., 2012). Wang W. et al. found that CD8+ T cells activated by immunotherapy enhanced the occurrence of lipid peroxidation in tumor cells, which then initiated ferroptosis, further enhancing the anti-tumor effect of immunotherapy (Wang et al., 2019). It suggests that the ferroptosis is involved in T cell mediated cancer immunity. There is a lack of research on the correlation between ferroptosis and immune response.

More and more evidence highlights the important role of ACSL4 in regulating the proliferation and apoptosis of cancer cells. Sung et al. found that ACSL4 was overexpressed in HCC tissues and cells (Sung et al., 2007). Arachidonic acid drives ACSL4 ubiquitination through substrate-induced post-translational regulatory mechanisms (Kan et al., 2014). Recent studies have shown that ACSL4 also increased GLUT1-mediated O-Glcnacylation promotes hepatocellular carcinoma cell growth and survival. In addition, ACSL4 acts as an activator of mTOR signaling, increasing HCC cell growth and inhibiting apoptosis (Wang J. et al., 2020). In breast cancer, ACSL4 promotes breast cancer cell proliferation, invasion and migration through the same mechanism (Orlando et al., 2015). Overexpression of ACSL4 is associated with the development of colon cancer. Apatinib promotes the ferroptosis in CRC cells by targeting ELOVL6 and subsequently regulating ACSL4 expression (Tian et al., 2021). Studies in human glioma have found that ACSL4 expression is down-regulated and iron death is also reduced. Therefore, ACSL4 is proposed to protect glioma cells and play an anti-proliferative role by activating the ferroptosis pathway, and highlights the key role of ACSL4 in regulating ferroptosis in the protection of glioma (Cheng et al., 2020). To analyze ACSL4 expression levels in different cancers, this study analyzed ACSL4 mRNA differential expression in 32 cancer types from Oncomine database and TIMER database compared with normal tissues. The two data sets were consistent: high expression of ACSL4 in colorectal cancer and liver cancer, low expression in breast cancer and central nervous tumor. It’s both elevated and decreased in pancreatic cancer. In addition, the expression was inconsistent in renal cell carcinoma, with high expression in Oncomine and down expression in TIMER, which may be due to differences in data sources and standardized methods of different databases. We also added the analysis results of GEPIA and found that ACSL4 expression was low in BRCA. In addition, the protein expression pattern of ACSL4 was analyzed by UALCAN database, and it was found that ACSL4 was highly expressed in colorectal cancer and low in breast cancer. Further, the prognostic value of ACSL4 in different cancers was evaluated in these databases, and we found that the prognosis of ACSL4 in breast cancer and lung cancer was consistently poor. To be specific, the GEO dataset analyzed by PrognoScan indicates that high expression of ACSL4 is associated with poor prognosis in Colorectal cancer and Brain cancer, and low expression of ACSL4 is associated with poor prognosis in Lung and Breast cancer. Similarly, low expression of ACSL4 in BRCA, LUAD, BLCA, CESC, HNSC, PAAD, STAD and TGCT showed poor prognosis in Kaplan-Meier database. GEPIA explored the poorer prognosis of ACSL4 low expression in ACC, KIRC, LGG, PCPG, and SKCM. These results suggest that ACSL4 has potential prognostic value in breast cancer, lung cancer, skin malignant melanoma and other cancers, and can be used as a biomarker reflecting the prognosis.

Genetic structural variation in the human genome can exist in many forms (Redon et al., 2006). Single nucleotide polymorphism (SNP) is considered to be the main form of structural variation, and CNV is also widely existed, which is associated with the occurrence and development of various cancers (Zhou et al., 2019; Wu et al., 2020; Zhong et al., 2020). There are few studies on the relationship between ACSL4 gene alteration and cancer. In this study, mixed-cancer panel found that ACSL4 had different degrees of genetic changes in 21 cancers, among which ACSL4 was most prone to genetic changes in Endometrial carcinoma, Melanoma and Sarcoma. In the cervical Squamous cell carcinoma, pleural Mesothelioma and Glioblastoma, all the cases were mutation. In Renal Clear cell carcinoma, Hepatocellular carcinoma and well-differentiated Thyroid cancer, Amplification occurred in all cases. Deep deletion occurred only in Seminoma in all cases. In addition, we found that patients with ACSL4 mutations had poor OS and PFS.

In recent years, more and more attention has been paid to the molecular classification of endometrium, which was mainly divided into four subtypes, which were believed to be caused by driver changes, i.e. POLE EDM, TP53 mutation or MMR defect, with significantly different prognosis (León-Castillo et al., 2020). Oxidative stress (OS) played an important role in melanoma metastasis through excessive production of reactive oxygen species (ROS). Other studies have shown that ionizing radiation (IR) not only induced the production of ROS in tumor cells, but also induced ACSL4 expression. ACSL4 preferentially utilized arachidonic acid as a substrate, resulting in increased lipid peroxidation and ferroptosis, thus exerting antitumor activity (Li G. et al., 2020). This is also consistent with the poor prognosis of the low expression of ACSL4 in melanoma in this study. We further analyzed ACSL4 single nucleotide variation (SNV) using GSCA. The results showed that the most variation was found in UCEC and SKCM, and the prognosis of ACSL4 mutant was worse in SKCM. CNV analysis showed that ACSL4 CNV was positively correlated with ACSL4 expression in 10 cancers, which was consistent with cBioPortal results. The prognosis was worse in patients with copy number deletion in KIPR, CESC, and LAML, and worse in patients with copy number amplification in UCEC.

DNA methylation is a common epigenetic modification by linking methyl groups to the C5 site of cytosine (5mC) in the CpG environment (Cao et al., 2019). Hypomethylation has been found to be widespread in cancer progression (Muhammad et al., 2021; Sugiura et al., 2021). Hypomethylation of ACSL4 in BRCA, BLCA, LIHC, STAD and TGCT was found in the UALCAN database. In GSCA, we found that ACSL4 expression was negatively correlated with methylation levels in 19 cancers. Interestingly, in LIHC, ACSL4 overexpression may be associated with hypomethylation of ACSL4 and a worse prognosis. This is consistent with the correlation between
ASLC4 mRNA expression and prognosis in LIHC, that is, high expression of ASLC4 leads to worse prognosis. A previous study also found that hypomethylated CpG sites of ASLC4 were associated with an increased risk of non-alcoholic fatty liver disease (NAFLD) (Zhang et al., 2018). These results suggest that hypomethylation of ASLC4 may be one of the epigenetic regulatory mechanisms in many cancers.

Immune evasion is an important marker of cancer and has long been considered as a basic process of tumor formation and progression (Chen and Mellman, 2017; Lei X. et al., 2020). The prognostic value of immune-infiltrating cells has been extensively studied in various malignancies, but ASLC4 has not been well studied in immuno-oncology (Ge et al., 2021; Yu et al., 2021). A major finding in this study was that ASLC4 expression was associated with levels of immune invasion across multiple cancer types. We found that ASLC4 expression was positively correlated with neutrophils, monocytes and CD4+T cells. As expected, ASLC4 was not consistently associated with levels of infiltration of CD8 T cells, Th1, Treg, B cells, macrophages, NK, and DC across different cancers. In BRCA and SKCM, ASLC4 was more closely related to the level of immune cell infiltration. In SKCM, ASLC4 expression level was not correlated with tumor purity, suggesting that there was no significant difference in ASLC4 expression level between tumor cells and tumor microenvironment. However, in BRCA, ASLC4 expression levels were significantly negatively correlated with tumor purity, suggesting sustained enrichment of ASLC4 in tumor cells. After adjusting for tumor purity, ASLC4 was significantly positively correlated with the level of immune cell infiltration in SKCM and BRCA. These findings suggest that ASLC4 plays an important role in the recruitment and regulation of immune-infiltrating cells in cancer. Patricia P. Yee et al. found in glioma studies that neutrophils play an anti-tumor role by inducing iron death in tumor cells through myeloperoxidase (MPO) and ASLC4 (Yee et al., 2020). CD4+T cells secrete a variety of cytokines, which directly or indirectly activate other immune cells (such as B cells and CD8+T cells) and enhance the anti-tumor activity of CTL. The original theory postulated that higher expression of immune cells in the early stages of carcinogenesis contributed to anti-tumor activity (Bindea et al., 2013). Our data analysis confirmed that ASLC4 and higher levels of immune cell infiltration were associated with better survival outcomes in BRCA and SKCM. As cancer progresses, the immune microenvironment may promote cancer cell growth while mediating immunosuppression. Myeloid suppressor cells are immature myeloid cells that also have immunosuppressive effects in the tumor microenvironment. In this study, it was found that cancers with high ASLC4 expression (LICH, COAD, STAD) had high levels of MDSC infiltration, while cancers with low ASLC4 expression (BRCA, KIRC, LUSC, SKCM) had high levels of MDSC infiltration, and had poor prognosis and survival in BRCA and SKCM. The prognosis was consistent with ASLC4 mRNA. Another study analyzed the possible association between tumor mutation load (TMB) prognosis and immune cell infiltration in SKCM. Studies have shown that SNPs are more frequent than insertions or deletions in SKCM, and patients with characteristic mutants in the high TMB group have poor survival outcomes and inhibit immune infiltration levels (Cao et al., 2019). These results suggest that ASLC4 may influence the level of tumor immune cell infiltration and ultimately affect patient survival, providing a reference for immunotherapy.

Considering that ASLC4 is genetically altered in a variety of cancers, we further analyzed whether there is a correlation between ASLC4 gene alteration or epigenetic modification and tumor immune cell infiltration level by using TIMER database. In this study, ASLC4 mutation was significantly positively correlated with CD4+T cells, CD4+T cells, B, DC, macrophages and CAFs infiltration levels in UCEC, while significantly negatively correlated with immune cell infiltration levels in SARC. In UCEC, Mutation mainly occurred, the level of immune cell invasion increased, and the prognosis and survival became worse. In SARC, Amplification and deep deletion mainly occurred, and the level of immune cell invasion decreased. When ASLC4 copy number is abnormal, the infiltration level of CAFs in BRCA and OV is reduced, and the prognosis of ASLC4 mRNA is poor. Although changes in the ASLC4 gene in our data affect immune cell infiltration levels in only a few cancer types, it also suggests that ASLC4 mutations or copy number abnormalities are closely associated with immune cell infiltration and affect prognosis in UCEC, SARC, BRCA and OV. It may be a potential immune and prognostic biomarker. This has not been suggested in previous studies.

In addition, this study further analyzed the association between ASLC4 and immune cell biomarkers in different cancers. It was found that ASLC4 had significant positive correlation with biomarkers of CD4+T cells, TAM, M2 macrophages, monocytes, DC, CAFs and MDSC in BRAC and SKCM. Notably, ASLC4 mRNA expression was low in both cancers and the prognosis was poor. This suggests that ASLC4 may affect prognosis by regulating immune cell recruitment and activation. In addition, ASLC4 was positively correlated with the markers of Exhaust T cells (CTLA4, HAVCR2, LA53, PDCD1) and Treg cells (CCR8, IL2RA, IL7R). There is increasing evidence that exhaust cells play an inhibitory role in the tumor microenvironment by changing signal cascade and epigenetic metabolism, attenuating effector cytotoxicity, reducing cytokine production, and regulating various inhibitory molecular receptors (Franco et al., 2020; Zeng et al., 2020). Increased infiltration of Exhaust T cells was found in many tumors, and patients with high expression of PD-L1 had better anti-PD1 treatment (Zheng et al., 2017; Guo et al., 2018). These results suggest that ASLC4 may affect the efficacy of immunotherapy and may become a potential predictive biomarker of immunotherapy.

By searching the CMap database, it was found that the compound with high similarity to ASLC4 was mainly inhibitor of Insulin growth factor 1 receptor protein tyrosine kinase. EGFR inhibitor etc. The insulin-like growth factor (IGF) signaling system plays a crucial role in human cancer. IGF-1 receptor (IGF-1R) inhibitors prevent binding of IGF-1 to IGF1R and subsequently inhibit down stream signaling, including PI3K/Akt pathway, exerting antitumor activity and being potential targets for cancer treatment (Pollard and Daniel, 2019). In this study, we speculate that the
mechanism of ACSL4 in cancer is closely related to the IGF signaling pathway. These highly similar compounds may contribute to the treatment of cancers with elevated ACSL4 expression, including colorectal cancer and liver cancer. However, CMap model is based on microarray data, and the accuracy of prediction may be limited. A large number of experimental studies are still needed to develop and verify the efficacy of the drug.

In this study, the expression and prognostic value of ACSL4 in different cancers were analyzed using multiple online public databases. Individual cancer results may be inconsistent due to differences in data collection and standardization across different databases. Therefore, further in vivo and in vitro experiments are needed to realize the mechanisms of ACSL4 in different cancer types at the cellular and molecular level. This is what the Bioinformatics Research Institute lacks. Although ACSL4 expression was found to be associated with immune cell infiltration and patient survival, it has not been demonstrated that ACSL4 affects patient survival through immune infiltration. ACSL4 is not only a sensitive monitor of ferroptosis, but also an important contributor of ferroptosis. The relationship between acSL4-mediated ferroptosis and immune infiltration and the clinical response to immunotherapy are also important topics for future research.

CONCLUSION

This study analyzed the expression of ACSL4 in generalized carcinoma, and for the first time analyzed the genetic and epigenetic changes of ACSL4 in different cancers, as well as its impact on survival and prognosis. In addition, ACSL4 mediates the level of immune cell infiltration in BRCA and SKCM, providing new ideas for personalized cancer immunotherapy.

ACSL4 is expected to be a potential prognostic and prognostic immunotherapy biomarker.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

AUTHOR CONTRIBUTIONS

ML and YY conceived the project. ML and XS extracted the information from the databases. XS conducted clinical data collection and analysis. YY and FC participated in data analysis. YY, XS and FC participated in discussion and language editing. ML wrote the manuscript. All authors have read and approved the final manuscript.

ACKNOWLEDGMENTS

We sincerely thank the public databases, including Oncomine, GEPIA, CCLE, UALCAN, HPA, cBioPortal, PrognoScan, Kaplan-Meier Plotter, TIMER, GSCA, and CMap for providing open access.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2022.812674/full#supplementary-material

REFERENCES

Bader, J. E., Voss, K., and Rathmell, J. C. (2020). Targeting Metabolism to Improve Cancer Immunotherapy. Mol. Cell. 78, 1019–1033. doi:10.1016/j.molcel.2020.05.034

Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., et al. (2013). Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer. Immunity 39, 782–795. doi:10.1016/j.immuni.2013.10.003

Biswas, S. K. (2015). Metabolic Reprogramming of Immune Cells in Cancer Progression. Immunity 43, 435–449. doi:10.1016/j.immuni.2015.09.001

Boroughs, L. K., and DeBerardinis, R. J. (2015). Metabolic Pathways Promoting Cancer Cell Survival and Growth. Nat. Cell Biol. 17, 351–359. doi:10.1038/ncb3124

Budczies, J., Seidel, A., Christopoulos, P., Endris, V., Kloor, M., Győrffy, B., et al. (2018). Integrated Analysis of the Immunological and Genetic Status in and across Cancer Types: Impact of Mutational Signatures beyond Tumor Mutational burden. Oncoimmunology 7, e1526613. doi:10.1080/2162402x.2018.1526613

Cao, T., Pan, W., Sun, X., and Shen, H. (2019). Integrated Expression of TET3 Predicts Unfavorable Prognosis in Patients with Ovarian Cancer—A Bioinformatics Integrative Analysis. J. ovariian Res. 12, 101. doi:10.1186/s13048-019-0575-4

Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., et al. (2012). The cBio Cancer Genomics portal: an Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discov. 2, 401–404. doi:10.1158/2159-8290.cd-12-0095

Chandrashekar, D. S., Bashel, B., Balasubramanya, S. A. H., Creighton, C. J., Ponce-Rodriguez, I., Chakravarthi, B., et al. (2017). UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia (New York, N.Y.) 19, 649–658. doi:10.1016/j.neo.2017.05.002

Chen, D. S., and Mellman, I. (2017). Elements of Cancer Immunity and the Cancer-Immune Set point. Nature 541, 321–330. doi:10.1038/nature21349

Chen, P. H., Cai, L., Huffman, K., Yang, C., Kim, J., Faubert, B., et al. (2019). Metabolic Diversity in Human Non-small Cell Lung Cancer Cells. Mol. Cell. 76, 838–851.e5. doi:10.1016/j.molcel.2019.08.028

Chen, J., Ding, C., Chen, Y., Hu, W., Lu, Y., Wu, W., et al. (2020). ACSL4 Promotes Hepatocellular Carcinoma Progression via C-Myc Stability Mediated by ERK/FBW7/c-Myc axis. Oncogenesis 9, 42. doi:10.1038/s41389-020-0226-z

Cheng, C., Geng, F., Cheng, X., and Guo, D. (2018). Lipid Metabolism Reprogramming and its Potential Targets in Cancer. Cancer Commun. (London, England) 38, 27. doi:10.1186/s40880-018-0301-4

Cheng, J., Fan, Y. Q., Liu, B. H., Zhou, H., Wang, J. M., and Chen, Q. X. (2020). ACSL4 Suppresses Glioma Cells Proliferation via Activating Ferroptosis. Oncol. Rep. 43, 147–158. doi:10.3892/or.2019.7149

Coleman, R. A., Lewin, T. M., and Musso, D. M. (2000). Physiological and Nutritional Regulation of Enzymes of Triacylglycerol Synthesis. Annu. Rev. Nutr. 20, 77–103. doi:10.1146/annurev.nutr.20.1.77
The page contains references to various scientific articles and studies. The references are in APA style and cover topics such as cancer research, metabolic pathways, and immune system biology. The text includes authors' names, year of publication, titles of the articles, and details such as journal names, page numbers, and DOI numbers. The references are arranged in a list, indicating the end of the text. The page is from the journal Frontiers in Genetics, as indicated by the logo and URL at the bottom of the page.
Wang, W., Green, M., Choi, J. E., Gijón, M., Kennedy, P. D., Johnson, J. K., et al. (2019). CD8(+) T Cells Regulate Tumour Ferroptosis during Cancer Immunotherapy. Nature 569, 270–274. doi:10.1038/s41586-019-1170-y

Wang, J., Wang, Z., Yuan, J., Wang, J., and Shen, X. (2020a). The Positive Feedback between ACSL4 Expression and O-GlcNAcylation Contributes to the Growth and Survival of Hepatocellular Carcinoma. Aging 12, 7786–7800. doi:10.18632/aging.103092

Wang, C. Y., Chiao, C. C., Phan, N. N., Li, C. Y., Sun, Z. D., Jiang, J. Z., et al. (2020b). Gene Signatures and Potential Therapeutic Targets of Amino Acid Metabolism in Estrogen Receptor-Positive Breast Cancer. Am. J. Cancer Res. 10, 95–113.

Woo, X. Y., Giordano, J., Srivastava, A., Zhao, Z. M., Lloyd, M. W., de Bruijn, R., et al. (2021). Conservation of Copy Number Profiles during Engraftment andPassaging of Patient-Derived Cancer Xenografts. Nat. Genet. 53, 86–99. doi:10.1038/s41588-020-00750-6

Wu, B., Lu, X., Shen, H., Yuan, X., Wang, X., Yin, N., et al. (2020). Intratumoral Heterogeneity and Genetic Characteristics of Prostate Cancer. Int. J. Cancer 146, 3369–3378. doi:10.1002/ijc.32961

Ye, X., Zhang, Y., Wang, X., Li, Y., and Gao, Y. (2016). Tumor-suppressive Functions of Long-Chain Acyl-CoA Synthetase 4 in Gastric Cancer. IUBMB Life 68, 320–327. doi:10.1002/iub.1486

Yee, P. P., Wei, Y., Kim, S. Y., Lu, T., Chih, S. Y., Lawson, C., et al. (2020). Neutrophil-induced Ferroptosis Promotes Tumor Necrosis in Glioblastoma Progression. Nat. Commun. 11, 5424. doi:10.1038/s41467-020-19193-y

Yen, M. C., Kan, J. Y., Hsieh, C. J., Kuo, P. L., Hou, M. F., and Hsu, Y. L. (2017). Neutrophil-induced Ferroptosis Promotes Tumor Necrosis in Glioblastoma Progression. Cancer Res. 77, 4013–4023. doi:10.1158/0008-5472.CAN-16-2606

Yu, Y., Wang, Z., Zheng, Q., and Li, J. (2021). GREB1L Overexpression Correlates with Prognosis and Immune Cell Infiltration in Lung Adenocarcinoma. Scientific Rep. 11, 13281. doi:10.1038/s41598-021-92695-x

Yuan, Q., Sun, N., Zheng, J., Wang, Y., Yan, X., Mai, W., et al. (2019). Prognostic and Immunological Role of FUN14 Domain Containing 1 in Pan-Cancer: Friend or Foe? Front. Oncol. 9, 1502. doi:10.3389/foonc.2019.01502

Zeng, Z., Wei, F., and Ren, X. (2020). Exhausted T Cells and Epigenetic Status. Cancer Biol. Med. 17, 923–936. doi:10.20892/j.issn.2095-3941.2020.0338

Zhang, R. N., Pan, Q., Zheng, R. D., Mi, Y. Q., Shen, F., Zhou, D., et al. (2018). Genome-wide Analysis of DNA Methylation in Human Peripheral Leukocytes Identifies Potential Biomarkers of Nonalcoholic Fatty Liver Disease. Int. J. Mol. Med. 42, 443–452. doi:10.3892/ijmm.2018.3583

Zhang, Y., Li, S., Li, F., Lv, C., and Yang, Q. K. (2021). High-fat Diet Impairs Ferroptosis and Promotes Cancer Invasiveness via Downregulating Tumor Suppressor ACSL4 in Lung Adenocarcinoma. Biol. direct 16, 10. doi:10.1186/s13062-021-00294-7

Zheng, C., Zheng, L., Yoo, J. K., Guo, H., Zhang, Y., Guo, X., et al. (2017). Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing. Cell 169, 1342–1356.e16. doi:10.1016/j.cell.2017.05.035

Zhong, Q., Fan, J., Chu, H., Pang, M., Li, J., Fan, Y., et al. (2020). Integrative Analysis of Genomic and Epigenetic Regulation of Endometrial Cancer. Aging 12, 9260–9274. doi:10.18632/aging.103202

Zhou, J., Wang, J., Hong, B., Ma, K., Xie, H., Li, L., et al. (2019). Gene Signatures and Prognostic Values of m6A Regulators in clear Cell Renal Cell Carcinoma - a Retrospective Study Using TCGA Database. Aging 11, 1633–1647. doi:10.18632/aging.101856

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Yu, Sun, Chen and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.